Trials
Sites
Patients Enrolled
Countries
What we do
ANZUP is the leading cancer cooperative clinical trials group that brings together all of the professional disciplines and groups involved in researching and treating below the belt (penile, bladder, kidney, prostate and testicular) cancers and conduct high quality clinical research.
ANZUP identifies gaps in evidence and areas of clinical need, collaborates with the leading clinicians and researchers in below the belt cancers, and communicate frequently and effectively with the broader community along the way.
What we do
ANZUP is the leading cancer cooperative clinical trials group that brings together all of the professional disciplines and groups involved in researching and treating below the belt (penile, bladder, kidney, prostate and testicular) cancers and conduct high quality clinical research.
ANZUP identifies gaps in evidence and areas of clinical need, collaborates with the leading clinicians and researchers in below the belt cancers, and communicate frequently and effectively with the broader community along the way.
Telehealth and Teletrials
Teletrials builds on the telehealth model and increases access to clinical trials for people with cancer living in rural and remote locations, or in self-isolation due to COVID-19. Teletrials also allows trials recruitment and activity to continue.
Teleheath and Teletrials
Teletrials builds on the telehealth model and increases access to clinical trials for people with cancer living in rural and remote locations, or in self-isolation due to COVID-19. Teletrials also allows trials recruitment and activity to continue.
Latest News
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
PSMA and FDG-PET as predictive and prognostic biomarkers TheraP biomarker Oct 2022 (1)Previously, results from the TheraP trial showed that treatment with lutetium-177 [¹⁷⁷Lu]Lu-PSMA-617 improved
Research Review, Speaker Series, Advances in the Management of Metastatic Prostate Cancer
This webinar was presented on May 18th, 2022 and involved two speakers’ presentations, followed by a panel discussion about Advances in the Management of Metastatic
ANZUP Annual Scientific Meeting 2022 Conference Review
Research Review has provided a review of the Annual Scientific Meeting of the Australia and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group that
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
PSMA and FDG-PET as predictive and prognostic biomarkers TheraP biomarker Oct 2022 (1)Previously, results from the TheraP trial showed that treatment with lutetium-177 [¹⁷⁷Lu]Lu-PSMA-617 improved
Research Review, Speaker Series, Advances in the Management of Metastatic Prostate Cancer
This webinar was presented on May 18th, 2022 and involved two speakers’ presentations, followed by a panel discussion about Advances in the Management of Metastatic
ANZUP Annual Scientific Meeting 2022 Conference Review
Research Review has provided a review of the Annual Scientific Meeting of the Australia and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group that